Pacific Biosciences Of California (PACB) Gains from Investment Securities (2022 - 2025)

Pacific Biosciences Of California has reported Gains from Investment Securities for 4 years, with the latest figure at -$18.7 million in Q1 2025.

• On a quarterly basis, Gains from Investment Securities fell 26614.29% year-over-year to -$18.7 million in Q1 2025; TTM through Dec 2025 was -$18.7 million, a 2100.0% decrease from a year earlier, with the FY2025 full-year figure at -$18.7 million, down 2100.0% from the prior year.
• Gains from Investment Securities was -$18.7 million for Q1 2025 at Pacific Biosciences Of California, down from -$2.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $12.3 million in Q1 2023, with the low at -$18.7 million in Q1 2025.
• Average Gains from Investment Securities over 4 years is -$176083.3, with a median of $515000.0 recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities jumped 1252.96% in 2023, then tumbled 26614.29% in 2025.
• Over 4 years, Gains from Investment Securities stood at $4.6 million in 2022, then tumbled by 76.08% to $1.1 million in 2023, then sank by 277.27% to -$2.0 million in 2024, then slumped by 858.97% to -$18.7 million in 2025.
• The last three Gains from Investment Securities figures came in at -$18.7 million (Q1 2025), -$2.0 million (Q4 2024), and $1.2 million (Q3 2024), per Business Quant data.